Trials / Terminated
TerminatedNCT03929497
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
Interventional, Open-label, Flexible-dose, Long-term Safety Extension Study of Lu AF11167 in Patients With Schizophrenia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AF11167 | Lu AF11167 - 2 or 4 mg/day; tablets, orally |
Timeline
- Start date
- 2019-04-22
- Primary completion
- 2020-09-01
- Completion
- 2020-09-14
- First posted
- 2019-04-26
- Last updated
- 2020-09-23
Locations
30 sites across 7 countries: Bulgaria, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
Source: ClinicalTrials.gov record NCT03929497. Inclusion in this directory is not an endorsement.